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Abstract. Severe burn injury is an acute inflammatory state 
with massive alterations in gene expression and levels of 
growth factors, cytokines and free radicals. During the cata-
bolic processes, changes in insulin sensitivity and skeletal 
muscle wasting (unintended loss of 5-15% of lean body mass) 
are observed clinically. Here, we reveal a novel molecular 
mechanism of Akt1/protein kinase Bα (Akt1/PKBα) regu-
lated via cross-talking between dephosphorylation of Thr
308 
and S-nitrosylation of Cys
296 post severe burn injury, which 
were characterized using nano-LC interfaced with tandem 
quadrupole time-of-fight mass spectrometry (Q-TOF)
micro 
tandem mass spectrometry in both in vitro and in vivo studies. 
For the in vitro studies, Akt1/PKBα was S-nitrosylated with 
S-nitrosoglutathione and derivatized by three methods. 
The derivatives were isolated by SDS-PAGE, trypsinized 
and analyzed by the tandem MS. For the in vivo studies, 
Akt1/PKBα in muscle lysates from burned rats was immuno-
precipitated, derivatized with HPDP-Biotin and analyzed as 
above. The studies demonstrated that the NO free radical 
reacts with the free thiol of Cys
296 to produce a Cys
296-SNO 
intermediate which accelerates interaction with Cys
310 to form 
Cys
296-Cys
310 in the kinase loop. MS/MS sequence analysis 
indicated that the dipeptide, linked via Cys
296-Cys
310, under-
went dephosphorylation at Thr
308. These effects were not 
observed in lysates from sham animals. As a result of this dual 
effect of burn injury, the loose conformation that is slightly 
stabilized by the Lys297-Thr308 salt bridge may be replaced 
by a more rigid structure which may block substrate access. 
Together with the findings of our previous report concerning 
mild IRS-1 integrity changes post burn, it is reasonable to 
conclude that the impaired Akt1/PKBα has a major impact on 
FOXO3 subcellular distribution and activities.
Introduction
Metabolic alterations that are produced by critical illness such 
as burn trauma are associated with a hypermetabolic/inflam-
matory state, increased protein catabolism (with resulting 
muscle wasting) and insulin resistance. Muscle wasting 
can lead to muscle weakness that can result in hypoventila-
tion, prolongation of dependence on mechanical ventilation, 
prolonged rehabilitation and even death (1-4). Insulin resis-
tance is a well established state in critically ill patients and is 
considered to play a key role in the metabolic derangements 
and muscle wasting. Binding of insulin to its receptor (IR) 
activates IR tyrosine kinase, which then phosphorylates IR 
substrates (IRSs). Phosphorylation of IRS1 and IRS2 trans-
duces the signal from IR to phosphatidylinositol-3-kinase 
(PI3-kinase) (4,5). Post-translational modifications (PTMs) 
of the insulin signaling system are considered to be major 
disease-dependent events that regulate glucose transport via 
GLUT-4 translocation and protein synthesis (6-12).
Akt1/PKBα is a critical downstream mediator of the 
IR/IRS/PI3-kinase pathway of the insulin signaling system 
(13-17). Akt1/PKBα consists of three structural features: 
the N-terminal pleckstrin homology (PH) domain, a large 
central kinase domain and a short C-terminal hydrophobic 
motif. High specific binding of the PH domain with 
membrane lipid products of PI3-kinase recruits Akt1/PKBα 
to the plasma membrane where phosphorylations of Thr308 
(pThr308, kinase domain) and Ser473 (pSer473, hydrophobic 
motif) occur. Phosphorylation of Thr308 partially stimulates 
kinase activity; however, additional phosphorylation of 
Ser473 is required for full activity. Activation is associated 
with a disordered to ordered transition of a specific αC helix 
of Akt1/PKBα via an allosteric mechanism. A salt bridge 
between the side-chain of Lys297 and the phosphate group 
of pThr308 in this αC helix contributes to an ordered acti-
vation segment from 292DFG to APE319 (18-21). Reversible 
dephosphorylations of Thr308 and Ser473 by protein phospha-
tase 2A (PP2A) and PH domain leucine-rich repeat protein 
phosphatase (PHLPPα) also occur in the Akt1/PKBα activa-
tion/deactivation cycle (22-25).
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In addition to the role of reversible phosphorylation/dephos-
phorylation in the regulation of Akt1/PKBα activity, this 
kinase is also reversibly inactivated by S-nitrosylation under 
conditions that result in persistently increased production of 
nitric oxide; such as after burn injury (13,26-29). Thiol titra-
tion and NMR data indicate that a disulfide bond (Cys
60-Cys
77) 
exists in the kinase PH domain (30). A second disulfide bond 
in the critical kinase activation loop (Cys
297-Cys
311) has been 
reported to be associated with dephosphorylation under oxida-
tive stress in vitro (31). In addition, it has been shown that 
when Cys
224 of Akt1/PKBα is mutated to a Ser residue, the 
kinase becomes resistant to NO donor-induced S-nitrosylation 
and inactivation; suggesting that this residue is a major 
S-nitrosylation acceptor site (28). In vivo S-nitrosylations of 
the insulin receptor β and Akt1/PKBα result in reductions in 
their kinase activities (27). These data suggest that the redox 
status of Akt1/PKBα, regulated by NO, is a second factor 
in the PTM that modulates kinase activity (via dynamic 
conformational changes) and thus GLUT-4 trafficking and 
protein synthesis. Nevertheless, to date, published data on the 
reversible phosphorylation(s) and S-nitrosylation(s) relevant 
to Akt1/PKBα activation, conformation and regulation have 
not provided conclusive information concerning their inter-
relationships nor critical S-nitrosylation sites involved in the 
kinase activation/deactivation cycle.
Recent technical developments have made it feasible to 
study the molecular details of these important processes. 
These techniques include: i) sensitive and site-specific proce-
dures for the detection of S-nitrosylation based upon nano-LC 
interfaced with tandem MS (32,33); ii) the Biotin-Switch 
method for qualitative discrimination of the thiol state between 
free, disulfide bonded and S-nitroylated cysteine residues 
under carefully defined conditions (34-39). Potential prob-
lems related to quantification with this technique have been 
discussed previously (33); and iii) highly specific anti-Akt1/
PKBα mAbs that can be used to immunoprecipitate quantities 
of protein that are sufficient to yield SDS-PAGE bands with 
Coomassie brilliant blue R-250 staining which are compatible 
with tandem MS analysis.
Burn injury-associated impairments in IRS1 signaling and 
attenuated IR-IRS-PI3K-Akt/PKB activation have been the 
major focuses of our research team (9,26,29,33). Significantly 
reduced phosphorylations of Ser473 and Thr308, as well as 
decreased Akt/PKB kinase activity were observed after burn 
injury [55% total body surface area (TBSA), day 3] and insulin 
stimulation (26). However, the interrelationship between 
impaired kinase activity and the loop disulfide bond (31) 
reported under oxidative stress remains unclear. In the present 
study we investigated the interaction between S-nitrosylation 
and phosphorylation at Cys
296-Lys
297 and Thr
308-Phe
309-Cys
310 
in the kinase loop at the proteomic level.
Specifically, the following issues need to be studied: i) the 
ability of Cys
296 to chemically quench elevated levels of free 
radicals, mainly nitric oxide; ii) loop conformational changes 
associated with two types of PTMs; iii) quantitative proteomics 
of Akt1/PKBα by stable isotope labeling in mice. In this study, 
we obtained MS/MS sequence data to characterize the thiol 
states of Cys296 in the kinase activity loop of Akt1/PKB. These 
measurements were possible despite the extremely low level of 
nitrosylated protein (at the 10
-15 pmol level, the chance of posi-
tive hits is ~25% with lysates prepared from 25 mg of soleus 
muscle). The biochemical role of S-nitrosylation at Cys
296 
was characterized as an intermediate state which reduces 
the kinetic barrier to form the disulfide bond with Cys
310 
within the activity loop. This occurs simultaneously with 
dephosphorylation of pThr
308 after burn injury. The facts that 
no other disulfide bonds associated with Cys
296 were detected 
suggest that they may be thermodynamically forbidden; due 
to geometry and/or dihedral strain. The data obtained with 
soleus muscle from burned and sham-treated rats indicates 
that NO-mediated formation of the Cys
296-Cys
310 disulfide 
bond (which likely downregulates kinase activity) plays a 
reciprocal role with formation of a Lys
297-pThr
308 salt bridge 
(which upregulates kinase activity) during disease-associated 
reversible activation/deactivation processes.
Materials and methods
Chemicals.  Acetonitrile  (ACN,  LC-MS  Chromasolv), 
formic acid (FA), glacial acetic acid, LC-MS grade water, 
dithiothreitol (DTT), iodoacetic acid, iodoacetamide, [Glu
1]-
fibrinopeptide B, methyl methanethiolsulfonate (MMTS), 
S-nitrosoglutathione (GSNO), sodium L-ascorbate, neocup-
roine, N,N-dimethylformamide (DMF), dimethyl sulfoxide 
(DMSO) were obtained from Sigma Chemical Co. (St. 
Louis, MO). SDS-PAGE Ready gels (4-15% Tris-HCl, cat. 
no. 161-1122), Laemmli sample buffer (cat. no. 161-0737) and 
Coomassie brilliant blue R-250 (no. 161-0436) were obtained 
from Bio-Rad. Trypsin profile IGD kits (cat. no. PP0100) 
were obtained from Sigma. Anti-Akt1/PKBα monoclonal 
antibody (cat. no. 05-798; lot, 26860) and inactive Akt1/PKBα 
(cat. no. 14-279) were purchased from Upstate (Charlottesville, 
VA, USA). Streptavidin agarose CL-4B (cat. no. 85881) was 
a product of Fluka (Milwakee, WI, USA). HPDP-Biotin 
(cat. no. 21341) and Iodoacetyl-LC-Biotin (cat. no. 21333) were 
purchased from Pierce (Rockford, IL, USA).
Mapping of cysteine residues in inactive Akt1/PKBα. Inactive 
Akt1/PKBα (10 µg, 0.18 nmol, in 10 µl stock solution) was 
transferred to a siliconized Eppendorf tube (0.6 ml) containing 
Laemmli sample buffer (2X, 10 µl, pH was adjusted to 8.0) and 
DDT (2 µl, 20 nmol, PBS, pH 8.0), and the solution was kept at 
95˚C for 5 min. Freshly prepared Iodoacetyl-LC-Biotin (15 µl, 
55 nmol, in DMF) was added to the denatured protein solution 
followed by stirring for an additional 15 min at room tempera-
ture. The resulting biotinylated Akt1/PKBα was purified by 
SDS-PAGE and stained with Coomassie brilliant blue R-250. 
The protein bands were excised (~1 mm size) and digested 
(Akt1/PKBα: trypsin 25, overnight at 37˚C) with a Trypsin 
Profile IGD kit according to the manufacturer's instructions. 
The biotinylated peptide mixture was captured by gentle 
stirring with streptavidin agarose CL-4B (30 µl packed) at 
room temperature for 1 h (final vol, 100 µl). The streptavidin 
beads were washed with PBS (0.5 ml x3), followed by water/
acetonitrile (ACN 10%, 0.5 ml x3). Biotinylated peptides were 
released from the streptavidin beads with formic acid (70%, 
100 µl) at room temperature for 15 min with brief vortexing. 
The supernatant containing biotinylated peptides was trans-
ferred to a new vial and the formic acid was evaporated with a 
SpeedVac. The biotinylated peptide mixture was resuspended INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  31:  740-750,  2013 742
in water/acetonitrile (ACN, 2%, with 0.1% FA, 70 µl), and the 
aliquots (10 µl) were injected into a Waters CapLC-tandem 
quadrupole time-of-fight mass spectrometry (Q-TOF) system.
Identification of disulfide bonds in inactive Akt1/PKBα. 
Inactive Akt1/PKBα (10 µg, 0.18 nmol, in 10 µl stock solu-
tion) was transferred into a siliconized Eppendorf tube 
(0.6 ml) containing Laemmli sample buffer (2X, 10 µl, 
pH 8.0) and iodoacetamide (2 µl, 20 nmol, PBS, pH 8.0). The 
mixture was maintained at 95˚C for 5 min and then stirred at 
room temperature for an additional 15 min. The Akt1/PKBα 
was purified by SDS-PAGE and stained with Coomassie 
brilliant blue R-250. The protein bands were processed as 
above.
Identification of NO acceptor sites in inactive Akt1/PKBα. 
Three samples of inactive Akt1/PKBα (10 µg, 0.18 nmol, in 
10 µl stock solution) were treated with GSNO (250 nmol, 50 µl 
PBS, pH 8.0, 200-fold excess/thiol group) for 1 h at room 
temperature in the dark in siliconized Eppendorf tubes (0.6 ml). 
Separation of Akt1/PKBα and GSNO was achieved by two 
successive acetone/water precipitations (0.3 ml, 70% ACN) at 
-40˚C for 10 min. The supernatants (containing GSNO) were 
removed by centrifugation at 14,000 x g for 2 min. The kinase 
pellets were resuspended in blocking buffer (100 µl, 20 mM 
Tris-HCl, pH 7.7, 2.5% SDS, 20 mM MMTS, 1 mM EDTA, 
0.1 mM neocuproine) at room temperature for 1 h with gentle 
stirring (1 mm ID x5 mm bar). Excess MMTS was removed 
by acetone (100%, 0.3 ml) precipitation (as above), and the 
protein pellets were resuspended in PBS (50 µl, pH 8.0). 
Freshly prepared iodoacetic acid (5 µl, 2 mM in PBS, pH 8.0), 
HPDP-Biotin (5 µl, 2 mM in DMSO), Iodoacetyl-LC-Biotin 
(5 µl, 2 mM in DMF) and sodium ascorbate (20 µl, 5 mM, 
PBS) were added to the three vials containing nitrosylated 
Akt1/PKBα, respectively. The reaction mixtures were stirred at 
room temperature for 15 min (iodoacetic acid and Iodoacetyl-
LC-Biotin) or 1 h for the thiol-disulfide exchange reaction. 
Aliquots of SDS sample buffer (2X, with 5% 2-mercapto-
ethanol, 50 µl) were added to the protein solutions, and the 
mixtures were incubated at 95˚C for 5 min. The derivatized 
proteins were processed as above. Carboxymethyl cysteine 
(CMC)-containing peptides, were neutralized with FA (5 µl) 
and sequenced via parent ion discovery trigged by the CMC 
immonium ion (134.02±0.05 mDa) as reported previously (33). 
Biotinylated peptides were sequenced with data-dependent 
acquisition after capture with streptavidin agarose beads. 
Ten-microliter aliquots of each final solution were injected 
into the CapLC-Q-TOF system.
Analysis of the Cys
296-Cys
310 disulfide bond formation 
in Akt1/PKBα after treatment with S-nitrosoglutathione. 
Inactive Akt1/PKBα (10 µg, 10 µl, 0.18 nmol) and freshly 
prepared GSNO (5 µl, 250 nmol, PBS, pH 8.0) were stirred in 
an Eppendorf tube (0.6 ml) in the dark at room temperature 
for 1 h. Separation of Akt1/PKBα and GSNO was performed 
with acetone/water (70%) as above. The kinase pellet was 
resuspended in PBS (10 µl), and SDS sample buffer (10 µl with 
iodoacetamide, 20 nmol) was added. The cysteine alkylation 
was performed at room temperature for 15 min. The protein 
samples were separated with SDS-PAGE Ready gels and 
digested as above. Aliquots of the final solution (10 µl) were 
injected into the CapLC-Q-TOF system.
Measurement of the free and disulfide bonded Cys
296 in 
Akt1/PKBα from soleus muscle of burned rats. Soleus 
muscle lysates from rats with third degree burn (40% 
TBSA) were prepared as previously described (29,33). The 
lysates (~10 mg/ml total proteins) were diluted to ~3-5 mg 
protein/ml protein with PBS, and filtered through 0.22-µm 
membranes. Immunoprecipitation was performed as follows. 
Anti-Akt1/PKBα mAb (clone A W24, 5 µg; Upstate) and 
prewashed protein G agarose beads (50 µl, packed) were kept 
at 4˚C (100 µl of PBS) for 1 h under gentle stirring. Without 
washing the beads, the soleus lysates (5 ml) were added and 
stirring was continued for an additional 90 min. Non-specific 
proteins were removed by washing with PBS (3X), Laemmli 
sample buffer (50 µl, pH 8) containing HPDP-Biotin (400 µM) 
was added and the mixtures were maintained at 95˚C for 
5 min. The procedures for SDS-PAGE separation and in-gel 
trypsin digestion were the same as described above.
The burn injury protocol was approved by the Committee on 
Research Animal Care and Use of the Massachusetts General 
Hospital (MGH). The MGH animal care facility is accred-
ited by the Association for Assessment and Accreditation of 
Laboratory Animal Care.
LC-MS/MS analysis. All experiments were performed using 
a Waters CapLC-Q-TOF
micro system (Waters Corporation, 
Milford, MA, USA) as previously described (32,33). An 
analytical column (75 mm ID x150 mm, C18 PepMap300, 
5 mm, LC Packings) was used to connect the stream select 
module of the CapLC with the voltage supply adapter for ESI. 
Peptide mixtures were loading onto the precolumn (C18 resin) 
at a flow rate of 15 µl/min. Dead volume from the CapLC 
injector to the precolumn was measured to be ~1.5 µl. After 
washing with mobile phase C (auxiliary pump, 0.1% formic 
acid in water/ACN, 2% ACN) for 2 min, the trapped peptides 
were back-washed from the precolumn onto the analytical 
column using the 10-position stream switching valve. Freshly 
prepared mobile phases A and C were sonicated under vacuum 
for ~25 min, and mobile phase B was treated in this way for 
5 min. The mobile phases were degassed every week, and 
the CapLC pumps were wet primed for 20 cycles. A linear 
gradient was used to elute the peptide mixture from mobile 
phase A (0.1% FA in water/ACN, 2% ACN) to mobile phase B 
(0.1% FA in ACN). The gradient was segmented as follow: 
isocratic elution with 2% B for 3 min, increasing B from 2 
to 70% (3-40 min), isocratic elution with 70% B (40-45 min) 
and decreasing B from 70 to 2% (over 2 min). The injector 
syringe (25 µl) was washed with degassed mobile phase A, 
and the injection volume was set as full loop mode (10 µl). 
The gradient flow rate was set at 1.5 µl/min before the 16/1 
Nanotee splitter and the pressure drop from the analytical 
column was ~800 psi. The pressure drop (or the flow splitting 
ratio) was adjusted and maintained with 20 µm ID capillary 
tubing at the waste outlet position of the Nanotee splitter. The 
gradient flow rate was ~95 nl/min. The electrospray voltage 
was set to ~3,000 V to obtain an even ESI plume at the 
beginning of the gradient (high water content). As a routine 
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parameters were adjusted to achieve ~45 counts/sec for the 
capillary tubing background peak (m/z 429). Sample cone and 
extraction cone voltages were set at 45 and 3 V, respectively. 
The instrument was operated in positive ion mode with the 
electrospray source maintained at 90˚C. The instrument 
was calibrated with synthetic human [Glu
1]-fibrinopeptide B 
(100 fmol/µl in acetonitrile/water, 10:90, 0.1% formic acid, 
v/v) at an infusion rate of 1 µl/min in TOF MS/MS mode. 
The peptide was selected at m/z 785.8 and focused into the 
collision cell containing argon gas at ~3x10
-5 Torr; the colli-
sion energy was set at 35 V. Instrument resolution for the 
[Glu
1]-fibrinopeptide B parent ion, m/z 785.84, was found to 
be 5,250 FWHM. All data were acquired and processed using 
MassLynx 4.1 software. For parent ion discovery triggered by 
the CMC immonium ion (134.02±0.03 Da), the survey low and 
high collision energies were set at 5 and 30 V, respectively. 
MS survey data were collected in continuum mode over the 
m/z 100-1,200 range. Data-dependent acquisition (DDA) was 
set from 450 to 1,500 m/z for the biotinylated peptides. Scan 
time was in the range of 1.9-3.8 sec (depending upon sample 
conditions), and the inter-scan delay was 0.1 sec. MS to MS/MS 
switch criteria were dependent upon the reporter ion intensity 
(5 counts/sec) and detection window (2.3 Da, charge status). 
The instrument was switched from MS/MS back to MS after 
5 sec without intensity restriction.
Evaluation of the S-nitrosylated cysteine site. Confirmations 
of the S-nitrosylation sites were performed by the following 
three step procedure. i) For parent ion discoveries by 
continuum MS survey, the peptide mass tolerance was 
0.2 Da for the CMC immonium ion. Under these conditions, 
only a few false positive ions were observed and these were 
eliminated manually from the expected CMC parent ion list. 
ii) The positively discovered parent ions were analyzed with 
PepSeq of MassLynx V4.1 software; oxidation of methionine 
was searched as a variable modification. iii) For peptides, 
with MS/MS scores <35, manual interpretations of candidate 
parent ions were performed with the following procedure: 
continuum MS/MS spectra were smoothed, the upper 
80% was centroided and cysteine residues were confirmed 
with three different thiol-specifically derivatized y ions. 
Cysteine residue monoisotopic mass C3H5NOS = 103.01 Da 
was  replaced  with  CMC  residue  monoisotopic  mass 
C5H7NO3S = 161.01 Da, HPDP-Biotin derivatized adduct 
residue monoisotopic mass C22H37N5O4S3 = 531.20 Da and 
Iodoacetyl-LC-Biotin derivatized adduct residue monoisotopic 
mass C21H35N5O4S2 = 485.21 Da, respectively.
Results and Discussion
It has been reported that NO production is elevated by stressors 
such as burn injury and in patients with type 2 diabetes (29-41). 
It has also been shown that the Cys
297-Cys
311 disulfide bond 
in the critical kinase activation loop of Akt1/PKBα may be 
formed in association with dephosphorylation under oxida-
tive stress in vitro (31). Thus, we hypothesized that reversible 
S-nitrosylation at either Cys296 or Cys310 in the kinase active 
loop may be a second PTM factor which complements revers-
ible phosphorylation at Thr
308 in the regulation of kinase activity 
and we sought to determine how S-nitrosylation interacts with 
phosphorylation during the Akt1/PKBα activation cycle (22). 
To address these issues, GSNO was used as the only NO donor 
in a model S-nitrosylation system to randomly target the seven 
cysteine residues of the kinase at pH 8. Vicinal Cys
296 and 
Cys
310 take advantage of the pKa for dissociation of the thiol 
to thiolate, and these electron-rich thiolate groups can lead to 
formation of an intradomain disulfide bond. Under these condi-
tions, intracellular free cysteine residues, and cysteines at the 
kinase surface without interactions or located in hydrophobic 
environments (i.e. high pKa), are unlikely to be affected by 
GSNO. In contrast, Cys
296 and Cys
310, which may have low pKa 
values due to weak interactions with vicinal residues inside the 
loop, are potential S-nitrosylation sites as predicted from the 3D 
structure of the kinase (19). NO donors, such as thioredoxin and 
thiol/disulfide oxidoreductases were excluded from the system 
to prevent possible interferences (42,43); however, a small 
amount of 2-mercaptoethanol (~0.05% v/v) was necessary to 
prevent oxygen effects.
The simple, but well-defined, S-nitrosylation reaction model 
was used to probe for particular NO acceptor sites in human 
Akt1/PKBα (inactive, 89% pure containing 2-mercaptoethanol 
and EGTA; Upstate) in three steps. i) Mapping of all cysteine 
residues with DTT reduction, Iodoacetyl-LC-Biotin alkylation 
and affinity capture provided relative MS ionization efficacies 
and charge states. ii) Detection of disulfide bonds with and 
without GSNO, provided an understanding of NO-mediated 
disulfide bond formation. The concentrations of the NO donor 
used here were similar to the levels used in reported studies 
(35-37). iii) MS/MS pinpointed the S-nitrosylated sites with 
three different thiol-specific derivatives. As indicated above, 
false-negatives may occur with the Biotin-Switch method 
(33), whereas false-positives are more common with the other 
methods; however, thiolether derivatives can be identified with 
MS/MS data. The findings of these studies were used to study 
the biological consequences of S-nitrosylation of Akt1/PKBα 
in soleus muscle from burned rats. This in vivo system was 
used because soleus muscle is an insulin-sensitive tissue with 
high levels of IRS-1.
A base peak intensity (BPI) nano-LC chromatogram 
of all seven affinity captured cysteine residues that were 
biotinylated with Iodoacetyl-LC-Biotin is shown (Fig. 1A). 
Cysteine residue monoisotopic mass of C3H5NOS = 103.01 Da 
was replaced with derivatized Cys residue monoisotopic 
mass of C21H35N5O4S2 = 485.21 Da. The relative simplicity 
of the nano-LC chromatogram indicates the high purifica-
tion efficacy for removing non-biotinylated tryptic peptides 
from  streptavidin  agarose  beads.  Three  predominate 
TOF MS tryptic parent ions were identified; m/z 639.79 
(T41, M+2H+ = 639.83) eluting at 50.5 min, m/z 1088.49 (T9, 
M-CH4+2H
+ = 1088.03) eluting at 51.5 min and m/z 924.67 
(T44, M+3H
+ = 924.43) eluting at 53 min are doubly and 
triply charged tryptic peptides containing Cys
296, Cys
310 and 
Cys
60, respectively. Fig. 1B shows the parent ions co-eluting at 
~53 min as well as the charge state assignments. Parent ions 
m/z 924.67 (T44, M+3H+ = 924.43) and m/z 1386.51 (T44, 
M+2H+ = 1386.14) are triply and doubly charged ions from the 
same tryptic peptide, 308TFCGTPEYLAPEVLEDNDYGR328, 
which  contains  Cys310.  Parent  ion  m/z  1266.09  (T58, 
M+3H
+ = 1266.41) is triply charged and derived from the peptide, 
437YFDEEFTAQMTITPPDQDDSMECVDSER
465, which INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  31:  740-750,  2013 744
contains Cys460. Parent ion m/z 815.87 (T11, M+2H+ = 815.93) 
is doubly charged from the peptide, 77CLQWTTVIER86, which 
contains Cys
77. Parent ion m/z 1088.49 resulted from CH4 
neutral loss from m/z 1096.48. Fig. 1C shows TOF MS parent 
ions that co-eluted at ~50.8 min; chromatographic peak tailing 
the most intense peak at 50.5 min. Parent ions m/z 731.33 (T9, 
M+3H+ = 731.03) and m/z 1096.46 (T9, M+2H+ = 1096.04) 
are triply and doubly charged ions from the same tryptic 
peptide, 49ESPLNNFSVAQCQLMK64, which contains Cys60. 
Parent ion m/z 639.79 (T41, M+2H+ = 639.83) is a doubly 
charged ion from the tryptic peptide, 
290ITDFGLCK
297, 
which contains Cys
296. Fig. 1D shows the TOF MS parent 
ions that co-eluted at ~53.5 min. Parent ion m/z 829.00 (T45, 
M+3H+ = 829.05) is triply charged and derived from the 
tryptic peptide, 
329AVDWWGLGVVMYEMMCGR
346, which 
contains Cys
344. Parent ion m/z 872.70 (T32, M+3H
+ = 872.43) 
is triply charged and derived from the tryptic peptide, 
223LCFVMEYANGGELFFHLSR241, which contains Cys224. 
No doubly charged T58, T45 or T32 ions were observed. It is 
clear that the ionization efficacies for the peptides containing 
Cys296 (M+2H+), Cys310 (M+2H+ and M+3H+), Cys60 (M+2H+ 
and M+3H+) and Cys77 (M+2H+) are much higher than for the 
triply charged peptides containing Cys
460 (M+3H
+), Cys334 
(M+3H
+) and Cys
224 (M+3H
+) under the same conditions.
Figure 1. Mapping of cysteine residues in inactive Akt1/PKBα. (A) Base peak intensity (BPI) nano-LC chromatogram of affinity capture of all seven cysteine 
residues that were biotinylated with Iodoacetyl-LC-Biotin. Sample preparation: see materials and methods section for details. Column conditions: 75 mm ID 
x150 mm, C18 PepMap300, 5 mm, under linear gradient conditions at a flow rate 95 nl/min. (B) TOF MS analysis of parent ions co-eluted at retention time of 
~53 min. Parent ions m/z 924.67 and 1386.51 are triply and doubly charged ions from the same tryptic peptide 
308TFCGTPEYLAPEVLEDNDYGR
328 which 
contains Cys
310. Parent ion m/z 1266.09 is a triply charged ion from the tryptic peptide, 
437YFDEEFTAQMTITPPDQDDSMECVDSER
465, which contains 
Cys
460. Parent ion m/z 815.87 is a doubly charged ion derived from the tryptic peptide, 
77CLQWTTVIER
86, which contains Cys
77. The parent ion at m/z 1088.49 
results from CH4 neutral loss from m/z 1096.46 as shown in C. (C) TOF MS analysis of parent ions co-eluting at retention time of ~50.8 min. Parent ions 
m/z 731.33 and 1096.46 are triply and doubly charged ions from the same tryptic peptide, 
49ESPLNNFSVAQCQLMK
64, which contains Cys
60. Parent ion 
m/z 639.79 is doubly charged and is derived from tryptic peptide, 
290ITDFGLCK
297, which contains Cys
296. (D) TOF MS analysis of parent ions co-eluting at 
retention time of ~53.5 min. Parent ion m/z 829.00 is triply charged and derived from tryptic peptide, 329AVDWWGLGVVMYEMMCGR346, which contains 
Cys
344. Parent ion m/z 872.70 is triply charged and derived from tryptic peptide, 
223LCFVMEYANGGELFFHLSR
241, which contains Cys
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When Akt1/PKBα was treated with GSNO without cleavage 
of disulfide bonds and the free cysteine residues were alkylated 
with iodoacetamide, two intradomain disulfide bonds were 
identified: Cys
60-Cys
77 in the PH domain and Cys
296-Cys
310 
in the kinase active loop. The monoisotopic parent ion with 
m/z 821.35, shown in Fig. 2A, represents two tryptic peptides 
containing the Cys
296-Cys
310 disulfide bond in the kinase loop. 
The isotopic peaks at m/z 821.61 and m/z 821.35 are attributed to 
the M+1 and M+0 ions. A mass difference of 0.26 Da (expected 
0.25 Da) indicated four positive charges: two at N-terminals 
and two at side chains of the C-terminals of the dipeptides. 
The expected quadruply charged disulfide bond linked 
Cys
296 and Cys
310-containing peptides (T41-SS-T44, M+4H
+) 
were calculated to be m/z 821.38 [(894.45 + 2387.06 + 4)/4]. 
The monoisotopic parent ion with m/z 764.41, shown in 
Fig. 2B, represents the two tryptic peptides containing the 
Cys60-Cys77 disulfide bond in the PH domain. The quadruply 
charged state is calculated as m/z 764.66 (M+1) - 764.41 
(M+0) = 0.25 which indicates four positive proton charges. 
The quadruply charged disulfide bond linked Cys
60 and Cys
77 
containing peptides (T9-SS-T11, M+4H
+) are calculated as 
m/z 764.37 [(1806.86 + 1246.63 + 4)/4]. Without GSNO treat-
ment, only the Cys60-Cys77 disulfide bond was detected. The 
mass accuracies for the two measurements were found to be 
36 ppm (Cys296-Cys310 disulfide bond linked dipeptides) and 
78 ppm (Cys60-Cys77 disulfide bond linked dipeptides). The 
impact of GSNO on Cys
296-Cys
310 disulfide bond formation 
is demonstrated in Fig. 2C and D. The S-nitrosylation reac-
Figure 2. Detections of two intradomain disulfide bonds in Akt1/PKBα. (A) Detection of intradomain Cys296-Cys310 disulfide bond in the kinase loop. Inactive 
Akt1/PKBα (10 µg) was treated with GSNO and iodoacetamide (50 µM) in Laemmli sample buffer as in D. In-gel trypsin digestion was performed after 
SDS-PAGE separation (4-15% Tris-HCl). Monoisotopic parent ion at m/z 821.35, charge state 4. Expected quadruply charged disulfide linked Cys
296 and Cys
310 
containing the peptide at m/z 821.38. (B) Detection of the intradomain Cys
60-Cys
77 disulfide bond in the PH domain. Monoisotopic parent ion at m/z 764.41, 
charge state 4. Expected quadruply charged disulfide bond linked Cys
60 and Cys
77-containing peptide at m/z 764.37. (C) Free thiol state of Cys
310 in the kinase 
loop without NO donor. The triply charged parent ion m/z 815.99: 308TFCGTPEYLAPEVLEDNDYGR328 (expected: m/z 816.03, CAM derivative) represents 
the completely free thiol state of Cys
310, while the triply charged m/z 821.31 is not from disulfide linked Cys
296-Cys
310 dipeptides (expected charge state 4). The 
Cys
296-Cys
310 disulfide bond was not detected in the absence of the NO donor. (D) Nitric oxide promotes the formation of the Cys
296-Cys
310 disulfide bond in the 
kinase loop. Inactive Akt1/PKBα (10 µg) was treated with GSNO (250 nmol, 50 µl PBS, pH 8.0, 1 h at room temperature in dark) prior to alkylation with iodo-
acetamide and SDS-PAGE. The doubly charged m/z 816.35 ion is not from a Cys310-containing tryptic peptide (expected charge state 3), and quadruply charged 
m/z 821.33 occurs at the expense of diminished triply charged Cys
310 peptide. The free thiol of Cys
310 is completely converted into the disulfide bond with Cys
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tion without GSNO (Fig. 2C) shows the triply charged tryptic 
peptide, 
308TFCGTPEYLAPEVLEDNDYGR
328, [carboxy-
amidomethyl cysteine (CAM) derivative] containing Cys
310 at 
m/z 815.99 (expected monoisotopic parent ion, 816.03). The 
observed M+1 isotopic peak was at m/z 816.33. The differ-
ence between the isotopic M+1 and M+0 peak of 0.34 Da 
indicates three proton charges. In contrast, the triply charged 
ions at m/z 821.31 and 821.65 (difference = 0.31 Da) do not 
represent the quadruply charged Cys
296-Cys
310 dipeptides in 
Fig. 2C. The triply charged Cys
310-containing peptide was 
found to be totally absent with GSNO treatment as shown in 
Fig. 2D. The doubly charged ions at m/z 816.35 and 816.85 
(difference = 0.50 Da) are not related to the triply charged 
tryptic  peptide 
308TFCGTPEYLAPEVLEDNDYGR
328 
(CAM derivative) containing Cys
310 at m/z 815.99 as shown 
in Fig. 2C. In contrast, the ions at m/z 821.33 and 821.58 
(difference = 0.25 Da) are indeed from quadruply charged 
Cys
296-Cys
310-linked dipeptides. Since quadruply charged 
Cys
296-Cys
310-linked dipeptides are formed at the expense of 
triply charged Cys
310-containing peptide after GSNO treat-
ment, it is obvious that S-nitrosylation and disulfide bond 
formation occur simultaneously in the kinase loop.
We next sought to determine which cysteine residue is the 
NO acceptor that initializes Cys
296-Cys
310 disulfide bond forma-
tion. There are three possibilities for the two cysteine residue 
thiol states: single S-nitrosothiol, double S-nitrosothiols and 
nitroxyl disulfide. The last case (nitroxyl disulfide) can be ruled 
out from the list, since the expected net mass increases of 28 Da 
(NO - 2H = 30 - 2 Da) were not observed for the corresponding 
dipeptides. The second case, double S-nitrosothiols of Cys
296 
and Cys
310, may occur if both pKa values are acidic inside the 
kinase loop. The Biotin-Switch method was used to identify the 
S-nitrosothiol within the loop under gentle reaction conditions 
(GSNO 250 nmol, 1 h). In addition, two other thiol-specific 
reagents, iodoacetic acid and Iodoacetyl-LC-Biotin (leaving 
molecule: HI, fast and quantitative), were evaluated.
Table I shows the expected results of Cys296 S-nitrosylation 
in the kinase loop with the three different chemical modifi-
cations. The resulting S-nitrosylated Cys was reduced with 
ascorbate and then derivatized with iodoacetic acid to afford 
the CMC derivative (the Cys residue with a monoisotopic 
mass C3H5NOS = 103.01 Da was replaced by the CMC 
residue with a monoisotopic mass C5H7NO3S = 161.01 Da) 
for sequence analysis. The CMC derivative of the y2 ion of 
the doubly charged tryptic peptide, 290ITDFGLCK297, was 
confirmed at m/z 308.17 (expected 308.13 = 161.01 + 145.10+ 
2.02). The Cys HPDP-Biotin adduct (Cys residue monoisotopic 
mass C3H5NOS = 103.01 Da was replaced with the adduct 
residue monoisotopic mass C22H37N5O4S3 = 531.20 Da) was 
used for sequence analysis. The corresponding y2 ion of the 
Biotin-HPDP derivatized, 
290ITDFGLCK
297, was confirmed 
at m/z 678.29 (expected 678.32 = 531.20 + 145.10 + 2.02). 
The Cys Iodoacetyl-LC-Biotin adduct (Cys residue monoiso-
topic mass C3H5NOS = 103.01 Da was replaced with adduct 
residue monoisotopic mass C21H35N5O4S2 = 485.21 Da) was 
used for peptide sequence analysis. The corresponding y2 ion 
of Iodoacetyl-LC-Biotin derivatized, 
290ITDFGLCK
297 was 
confirmed at m/z 632.38 (expected 632.33 = 485.21 + 145.10 
+ 2.02). Since the y2 ions of 
296Cys-Lys
297 produced with the 
three different derivatization procedures were unambiguously 
observed it is likely that Cys
296 is a favorable S-nitrosylation 
site under the conditions used. Although studies with 
mutated Akt1/PKBα (Cys
224) indicated that Cys
224 is a major 
S-nitrosylation acceptor site in vitro (28), the biological role of 
S-nitrosylated Cys
224 in kinase regulation needs to be further 
explored. In the current study it was determined that significant 
S-nitrosylation of Cys
224 is improbable, since using the three 
alkylation approaches and trypsin digestion, the levels of posi-
tive ionization of Cys
224-containing peptides were below the 
level of detection. This failure in detection of S-nitrosylated 
Cys
224 may be a false-negative under our experimental condi-
tions and clearly warrants further investigation. Nevertheless, 
our findings clearly demonstrate that S-nitrosylated Cys
296 is 
directly relevant to the kinase activation regulation cycle.
One possible explanation for the kinetics of Cys
296-Cys
310 
disulfide bond formation in the kinase loop may be that there 
is a high kinetic barrier without GSNO. Due to its highly labile 
nature (44), S-nitrosylated Cys
296, which forms rapidly in the 
presence of GSNO, may function as an intermediate state. 
Since this intermediate is likely to have a lower kinetic barrier 
for Cys
296-Cys
310 disulfide bond formation, the overall speed 
of the reaction should increase greatly. It has been reported 
that trans-nitrosylation reactions between vicinal thiols can 
occur and accelerate disulfide bond formation (45). The well 
characterized Cys296-Cys310 disulfide bond can be used as a 
signature peptide for detection of S-nitrosylation of Cys296 
after immunoprecipitation. The separation of tryptic peptide 
mixtures with our nano-LC interfaced Q-TOFmicro is demon-
strated in Fig. 3 (bottom panel). The extracted mass ion peak 
m/z 821.62, as shown in Fig. 3 (top panel), is the M+1 isotopic 
peak of the quadruply charged dipeptides (the most intense 
isotopic peak due to a high number of carbon atoms).
The in vitro system allowed us to determine conditions 
that are favorable for evaluation of S-nitrosylation of Cys296 
by MS/MS and was useful for studying the mechanism of 
intradomain disulfide bond formation. The reason for using 
inactive Akt1/PKBα (unphosphorylated) in these studies was 
to find possible S-nitrosylation sites in relationship with the 
following published data: i) Akt1/PKBα undergoes transient 
phosphorylation/dephosphorylation which regulates the 
Table I. Characterization of the thiol-specifically modified Akt1/PKBα peptide 
290ITDFGLCK
297.
Chemical derivatives  Parent calc.  Parent found  y2 ion calc.  y2 ion found
CMC  953.45  953.42  308.13  308.17
HPDP-Biotin  1323.64  1323.68  678.32  678.29
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kinase activity conformation cycle (22); ii) kinase disulfide 
bond formation, Cys
297-Cys
311, and dephosphorylation at 
pThr308 are induced simultaneously by H2O2 oxidative stress 
in vitro (31); iii) high levels of nitric oxide production occur 
both after burn injury (29,42) and in diabetic patients (43). 
Previous results from our laboratory have indicated that 
there is S-nitrosylation at Cys296 in rat soleus muscle (33). 
A parent ion at m/z 690.83 containing Cys
296  (T41-T42: 
290ITCFGLCKEGIK
301) was observed with CAM immonium 
trigged parent ion discovery; however, MS/MS sequencing 
data were not obtained. As a continuation of these studies to 
explore S-nitrosylation in the kinase active loop, large amounts 
of rat soleus muscle lysate (~3-5 mg/ml total proteins, 3 ml 
for each experiment, day 4 after 40% TBSA, 3rd degree burn) 
were used. In the present study, detailed MS/MS analyses 
of HPDP-biotinylated free Cys296 peptide and Cys296-Cys310 
disulfide bound dipeptides of Akt1/PKBα were performed 
with lysates of rat soleus muscle after burn injury. The tryptic 
Figure 3. Nano-LC chromatogram of tryptic peptides of Akt1/PKBα and MS ion 821.62 chromatogram of soleus muscle. Top panel: mass ion chromatogram of the 
dipeptides m/z 821.62: M+1 isotopic peak of the quadruply charged dipeptides (intensity of M+0 monoisotopic peak is lower than M+1). Bottom panel: BPI chro-
matogram of the Akt1/PKBα tryptic peptides after immunoprecipitations and in-gel digestion from nano-LC interfaced with Q-TOF tandem mass spectrometry.
Figure 4. MS/MS sequence analysis of biotinylted free Cys296 peptide of Akt1/PKBα after burn injury. Rat soleus muscle lysates (30 mg total protein) were 
treated with anti-Akt1/PKBα mAb and in-gel biotination was performed with HPDP-Biotin. Parent ion m/z 662.84 (M+2H
+, expected 662.82) was sequenced. 
Cys residue monoisotopic mass C3H5NOS = 103.01 Da is replaced with the adduct residue monoisotopic mass C22H37N5O4S3 = 531.20 Da. A low sequence score 
18 was obtained from the parent ion with S/N = 3; however the critical diagnostic y2, y4 and y5 ions at m/z 678.29, 849.34 and 995.51 confirmed that trace 
amounts of free Cys
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parent ion derivatized from free Cys
296 after burn injury was 
observed at m/z 662.84 (M+2H
+, expected 662.82) and the MS/
MS sequence data are shown in Fig. 4. A low sequence score 
of 18 was obtained from the parent ion with S/N = 3. However, 
the critical diagnostic y2, y4 and y5 ions at m/z 678.29, 849.34 
and 995.51 confirmed that trace amounts of free Cys296 are 
indeed present after intradomain disulfide bond formation 
induced by burn injury. In addition, partial sequencing data for 
Cys
296-Cys
310 disulfide-linked dipeptides are shown in Fig. 5. 
The C-terminal y ion series of Cys
310-containing peptide, 
308TFCGTPEYLAPEVLEDNDYGR
328, was observed for 
the quadruply charged parent ion (T41-SS-T44, M+4H
+). 
Cys
296-Cys
310 disulfide-linked dipeptides were not observed in 
muscle lysates from sham-treated animals (negative controls). 
The chance of obtaining the MS/MS sequence using our in vivo 
experimental conditions is only ~20-25%. This indicates that 
one interpretable MS/MS outcome (score >25) is expected in 
four or five independent experiments in which three succes-
sive injections are performed. Nevertheless, these MS/MS data 
for peptides containing free Cys
296 and Cys
296-Cys
310-linked 
Figure 5. MS/MS sequence analysis of the Cys
296-Cys
310 disulfide-linked peptide with dephosphoryated Thr
308 in soleus muscle from burned rats. Partially 
sequenced Cys296-Cys310 disulfide-linked dipeptides: C-terminal y ion series (y3 to y9) of Cys310-containing peptide, 308TFCGTPEYLAPEVLEDNDYGR328, 
were observed from the quadruply charged parent ion (T41-SS-T44, M+4H
+).
Figure 6. Proposed mechanism for Akt1/PKBα kinase regulation by phosphorylation and S-nitrosylation in the muscle of burned rats. Phosphorylation of 
Thr
308 stabilizes the disordered loop structure between 
292DFG and APE
319 via a salt bridge with Lys
297 as illustrated in the loop Peptide 1, which upregulates 
Akt1/PKBα kinase activity. NO free radical production is increased after burn injury. A large portion of Cys296 undergoes S-nitrosylation at Cys296 (Peptide 2); 
however, some free Cys
296 remains (Peptide 3). S-nitrosylation activates Cys
296-Cys
310 intradomain disulfide bond formation (Peptide 4). S-nitrosylation at 
Cys
296 is associated with dephosphorylation of Thr
308 and inaccessibility to the kinase site; which downregulates kinase activity.LU et al:  NITRIC OXIDE PROMOTES THE DISULFIDE BOND IN Akt1/PKBα 749
dipeptides are sufficient to verify our hypothesis that 
S-nitrosylation promotes intradomain disulfide bond formation 
and dephosphorylation at pThr
308 after burn injury as illustrated 
in Fig. 6. Due to its high lability of Cys
296-SNO, direct identifi-
cation of this species in vivo was not possible.
S-nitrosylation of Akt1/PKBα is a key factor for under-
standing the regulation of glucose transport and downstream 
protein synthesis. A recent study demonstrated that blockade 
of iNOS prevents the S-nitrosylations of Akt and IRS-1 and 
results in insulin resistance in vivo (46). Although it is clear 
that two PTMs of Akt1/PKBα, phosphorylation at Thr
308 
and S-nitrosylation at Cys
296, are critical for the regulation 
of Akt1/PKBα activity under stress conditions, there are 
still many unanswered questions concerning how reversible 
phosphorylation/dephosphorylation and S-nitrosylation/deni-
trosylation modulate Akt1/PKBα activity. For example, it has 
been reported that the Cys
296-Cys
310 disulfide bond is present 
only when there is binding of substrate to the active kinase 
loop and phosphorylation at Thr
308 (25); indicating that both 
disulfide bond formation as well as phosphorylation of Thr
308 
are important for kinase activity. In contrast, this disulfide 
bond was not observed under similar conditions in two studies 
of the ternary structure of the kinase (19,21); even though, 
oxidative stress was shown to induce dephosphorylation of 
pThr
308 and disulfide bond formation in the kinase loop in an 
in vitro study (31).
In summary, our data establish that Cys
296 is an important 
S-nitrosylation site in the kinase loop of Akt1/PKBα under 
gentle reaction conditions: i) iodoacetic acid as previously 
described; ii) the HPDP-Biotin switch method; and iii) the 
Iodoacetyl-LC-Biotin method to ensure indirect capture of 
Cys
296-SNO which may be undetectable with HPDP-Biotin. 
The corresponding derivatized y2 ions (
296Cys-Lys
297) in the 
tryptic peptide (Ile-Thr-Asp-Phe-Gly-Leu-Cys-Lys) were 
obtained with mass sequences to eliminate false-positive 
discovery. Although no other S-nitrosylated cysteine residues 
were detected, it is possible that S-nitrosylations at Cys
224, 
Cys
344 and Cys
460 were missed due to very low ionizations (i.e., 
false-negative discoveries). As a consequence of S-nitrosylation 
at Cys
296, there is rapid disulfide bond formation with vicinal 
Cys
310 in the kinase loop, which alters kinase substrate recog-
nition (47) as well as Akt-FOXO switch (48). This affords a 
stable disulfide bond linked quadruply charged parent ion at 
m/z 821.35 (M+4H
+). Partial sequencing data for Cys
296-Cys
310 
linked dipeptides from soleus muscle lysates indicated that 
burn injury is associated with both dephosphorylation of 
pThr
308 and disulfide bond formation. These two types of 
PTMs may provide insights for understanding negative coop-
erative effects on reduced Akt/PKB kinase activity after burn 
injury as previously reported by our laboratory (26). Although 
our results have provided important mechanistic information, 
quantitative measurements of Thr
308/pThr
308 and free Cys
296/
SNO-Cys
296/bound Cys
296 in patients with burn injury and 
type 2 diabetes remain very challenging.
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